Investigation of Nutrilite Glucose Health Herbal Drink on Prediabetes Persons

NCT07690735 | Completed

• 1 other identifier: IS20220010RDBJSP02V1
• Study Type: interventional
• Target: 117
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this two arms, randomized, double-blind controlled trial is to study whether Nutrilite herbal drink could ameliorate blood glucose level in prediabetes population. 100 eligible Participants aged 18-65 years will be enrolled in one center. Participants will be randomly assigned to two study groups, with 50 subjects in each group.Study subjects will be administrated with either the Nutrilite product or a placebo drink for two months (8 weeks). And up to three study visits will be made by the subject over a 2-month period intervention. Researchers will compare two groups to see if consumption of Nutrilite herbal drink could significantly ameliorate blood glucose level at the end of the study.

Conditions

PreDiabetes

Outcome Measures

Primary Outcomes (2)

• Changes in blood glucose level（fasten plasma glucose）

  fasten plasma glucose

  baseline day 0, day 56

• Changes in blood glucose level (2-hour postprandial blood glucose levels)

  2-hour postprandial blood glucose levels

  baseline day 0, day 56

Secondary Outcomes (6)

• changes of glycated hemoglobin

  baseline day 0, day 56

• Changes in islet function (insulin level)

  baseline day 0, day 56

• changes in islet function (C-peptide level)

  baseline day 0, day 56

• Changes in blood lipids profile (TC)

  baseline day 0, day 56

• Changes in blood lipids profile (TG)

  baseline day 0, day 56

Study Arms (2)

nutrilite glucose health herbal drink

EXPERIMENTAL

Dietary Supplement: Nutrilite Glucose health herbal drink

placebo drink

PLACEBO COMPARATOR

Dietary Supplement: Placebo drink

Interventions

Nutrilite Glucose health herbal drink DIETARY_SUPPLEMENT

1 sachet per time, 3 times a day after meal

nutrilite glucose health herbal drink

Placebo drink DIETARY_SUPPLEMENT

1 sachet per time, 3 times a day after meal

placebo drink

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects, age 18-65 years.
• Participants who meet the following diagnostic criteria based on the "Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)" and "Guiding Principles for Evaluation of Health Food Efficacy": fasting blood glucose levels of \>5.6 and \<7.0 mmol/L, and/or 2-hour postprandial blood glucose levels ≥7.8 and \<11.1 mmol/L.
• Participants agree not to take any dietary supplements or foods for blood glucose controlduring the study.
• Participants understand the test procedure, read, and sign an appropriate Informed Consent Form indicating their willingness to participate.

You may not qualify if:

• Participants diagnosed with type 1 diabetes mellitus.
• Malignant diseases: patients with severe lung, cardiovascular, blood and hematopoietic system, central nervous system or other system diseases, as well as tumor patients
• Participants who developed diabetic ketosis, acidosis, and infection within the past 3 months.
• Participants who participated in other clinical trials within the past 3 months.
• Women who are pregnant or breastfeeding, or who plan to become pregnant during the trial;
• Participantes who are allergic to the test samples.
• PI considers that volunteers cannot fully cooperate with the trial arrangement.

Sponsors & Collaborators

• Amway (China) R&D Center: lead
• Xiyuan Hospital of China Academy of Chinese Medical Sciences: collaborator

Study Sites (1)

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

Beijing, China

Location

MeSH Terms

Conditions

Prediabetic State

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2023
• First Posted: July 8, 2026
• Study Start: December 4, 2023
• Primary Completion: April 30, 2026
• Study Completion: May 30, 2026
• Last Updated: July 8, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)